Hikal Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
3,468
- Stock Symbol
-
524735
- Share Price
-
$4.15
- (As of Friday Closing)
Hikal General Information
Description
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
Contact Information
Website
www.hikal.comCorporate Office
- Great Eastern Chambers
- Sector 11, CBD-Belapur, Navi Mumbai
- Mumbai, Maharashtra 400614
- India
Corporate Office
- Great Eastern Chambers
- Sector 11, CBD-Belapur, Navi Mumbai
- Mumbai, Maharashtra 400614
- India
Hikal Stock Performance
As of 20-Jun-2025, Hikal’s stock price is $4.15. Its current market cap is $512M with 123M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.15 | $4.15 | $3.64 - $5.49 | $512M | 123M | 33.6K | $0.09 |
Hikal Financials Summary
As of 31-Mar-2025, Hikal has a trailing 12-month revenue of $218M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
|---|---|---|---|---|
| EV | 664,365 | 664,365 | 478,632 | 496,776 |
| Revenue | 218,027 | 218,027 | 213,648 | 249,659 |
| EBITDA | 39,430 | 39,430 | 32,554 | 31,552 |
| Net Income | 10,739 | 10,739 | 8,407 | 9,761 |
| Total Assets | 295,642 | 295,642 | 298,243 | 290,555 |
| Total Debt | 89,398 | 89,398 | 98,038 | 91,130 |
Hikal Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hikal Comparisons
Industry
Financing
Details
Hikal Competitors (6)
One of Hikal’s 6 competitors is Merck, a Corporation company based in Darmstadt, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck | Corporation | Darmstadt, Germany | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Lanxess Deutschland | Corporation | Cologne, Germany | ||||
| Taro Pharmaceutical Industries | Corporate Backed or Acquired | Haifa Bay, Israel | ||||
| Evonik Industries | Formerly PE-Backed | Essen, Germany |
Hikal Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hikal Patents
Hikal Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3156529-A1 | Substantially pure clarithromycin 9-oxime and its preparation thereof | Pending | 29-Oct-2019 | ||
| EP-4051289-A1 | Substantially pure clarithromycin 9-oxime and its preparation thereof | Inactive | 29-Oct-2019 | ||
| US-20230250124-A1 | Substantially pure clarithromycin 9-oxime and its preparation thereof | Pending | 29-Oct-2019 | ||
| EP-4051289-A4 | Substantially pure clarithromycin 9-oxime and its preparation thereof | Inactive | 29-Oct-2019 | ||
| CA-3153357-A1 | An industrial scale process for the preparation of prothioconazole | Pending | 17-Oct-2019 | A01N43/653 |
Hikal Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hikal ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
37.43 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Hikal FAQs
-
When was Hikal founded?
Hikal was founded in 1988.
-
Where is Hikal headquartered?
Hikal is headquartered in Mumbai, India.
-
What is the size of Hikal?
Hikal has 3,468 total employees.
-
What industry is Hikal in?
Hikal’s primary industry is Specialty Chemicals.
-
Is Hikal a private or public company?
Hikal is a Public company.
-
What is Hikal’s stock symbol?
The ticker symbol for Hikal is 524735.
-
What is the current stock price of Hikal?
As of 20-Jun-2025 the stock price of Hikal is $4.15.
-
What is the current market cap of Hikal?
The current market capitalization of Hikal is $512M.
-
What is Hikal’s current revenue?
The trailing twelve month revenue for Hikal is $218M.
-
Who are Hikal’s competitors?
Merck, Zydus Lifesciences, Lanxess Deutschland, Taro Pharmaceutical Industries, and Evonik Industries are some of the 6 competitors of Hikal.
-
What is Hikal’s annual earnings per share (EPS)?
Hikal’s EPS for 12 months was $0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
